Guidelines and literature

• 2022

  Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.

  HERRMANN, K. et al., Joint EANM, SNMMI and IAEA Enabling Guide: How to Set up a Theranostics Centre, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Springer Science and Business Media LLC (2022) pp. 2300–2309

• 2020

  Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study

  Strosberg, J. K., P. L.: Hendifar, A.: Yao, J.: Bushnell, D.: Kulke, M. H.: Baum, R. P.: Caplin, M.: Ruszniewski, P.: Delpassand, E.: Hobday, T.: Verslype, C.: Benson, A.: Srirajaskanthan, R.: Pavel, M.: Mora, J.: Berlin, J.: Grande, E.: Reed, N.: Seregni, E.: Paganelli, G.: Severi, S.: Morse, M.: Metz, D. C.: Ansquer, C.: Courbon, F.: Al-Nahhas, A.: Baudin, E.: Giammarile, F.: Taïeb, D.: Mittra, E.: Wolin, E.: O'Dorisio, T. M.: Lebtahi, R.: Deroose, C. M.: Grana, C. M.: Bodei, L.: Öberg, K.: Polack, B. D.: He, B.: Mariani, M. F.: Gericke, G.: Santoro, P.: Erion, J. L.: Ravasi, L.: Krenning, E. (2020). Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-020-04709-x

• 2020

  Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

  Ahmadzadehfar, H. R., K.: Baum, R. P.: Seifert, R.: Kessel, K.: Bogemann, M.: Kulkarni, H. R.: Zhang, J.: Gerke, C.: Fimmers, R.: Kratochwil, C.: Rathke, H.: Ilhan, H.: Maffey-Steffan, J.: Sathekge, M.: Kabasakal, L.: Garcia-Perez, F. O.: Kairemo, K.: Maharaj, M.: Paez, D.: Virgolini, I. (2020). Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/32383093. doi:10.1007/s00259-020-04797-9

• 2019

  Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma

  Novruzov, F. A., Jamil A: Allahverdiyeva, Zeynəb: Mehdi, Elnur: Giammarile, Francesco. (2019). Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma. Revista espanola de medicina nuclear e imagen molecular. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30665750.

• 2018

  Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse

  Delgado Bolton, R. C. G., F. (2018). Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: the offer that oncologists cannot refuse. Eur J Nucl Med Mol Imaging, 45(5), 822-823. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29333576: https://link.springer.com/content/pdf/10.1007%2Fs00259-017-3913-z.pdf. doi:10.1007/s00259-017-3913-z

• 2018

  EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

  Handkiewicz-Junak, D. P., T. D.: Bodei, L.: Aktolun, C.: Ezziddin, S.: Giammarile, F.: Delgado-Bolton, R. C.: Gabriel, M. (2018). EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging, 45(5), 846-859. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29453701: https://link.springer.com/content/pdf/10.1007%2Fs00259-018-3947-x.pdf: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978928/pdf/259_2018_Articl.... doi:10.1007/s00259-018-3947-x

• 2012

  Timing and optimized acquisition parameters for the whole-body imaging of (1)(7)(7)Lu-EDTMP toward performing bone pain palliation treatment

  Liu, C. B., J. R.: Liu, X.: Li, H.: Xiang, X.: Luo, Z.: Wang, Y.: Kuai, D.: Zhang, G.: Zaknun, J. J. (2012). Timing and optimized acquisition parameters for the whole-body imaging of (1)(7)(7)Lu-EDTMP toward performing bone pain palliation treatment. Nucl Med Commun, 33(1), 90-96. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22001721. doi:10.1097/MNM.0b013e32834d3c13

Nuclear Oncology

• 2020

  Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis

  WARD, Z.J., et al., Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis, The Lancet Oncology 21 8 (2020) 1077 - 1088.

PET, Oncology, Therapy

• 2021

  Neuroblastomas Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology

  SHULKIN, B.L., et al., Neuroblastomas Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology, Cambridge Scholars Publishing: Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology, (2021).

Radionuclide Therapy

• 2019

  Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis.

  Saravana-Bawan, B., Bajwa, A., Paterson, J., McEwan, A. J. B., & McMullen, T. P. W. (2019). Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clin Nucl Med, 44(9), 719-727. doi:10.1097/rlu.0000000000002646

• 2019

  NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE (2019)

  Hope, T. A., Abbott, A., Colucci, K., Bushnell, D. L., Gardner, L., Graham, W. S., . . . Strosberg, J. R. (2019). NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE. J Nucl Med, 60(7), 937-943. doi:10.2967/jnumed.118.230607

• 2019

  Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis.

  Yang, T., Zheng, S. Y., Jiao, J., Zou, Q., & Zhang, Y. (2019). Radioiodine remnant ablation in papillary thyroid microcarcinoma: a meta-analysis. Nucl Med Commun, 40(7), 711-719. doi:10.1097/mnm.0000000000001018

• 2019

  Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

  Yadav, M. P., Ballal, S., Sahoo, R. K., Dwivedi, S. N., & Bal, C. (2019). Radioligand Therapy With (177)Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol, 213(2), 275-285. doi:10.2214/ajr.18.20845

• 2018

  EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer (2018)

  Poeppel, T. D., Handkiewicz-Junak, D., Andreeff, M., Becherer, A., Bockisch, A., Fricke, E., . . . Gabriel, M. (2018). EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 45(5), 824-845. Retrieved from https://doi.org/10.1007/s00259-017-3900-4. doi:10.1007/s00259-017-3900-4

• 2018

  Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis.

  Levy, J., Zuckerman, J., Garfinkle, R., Acuna, S. A., Touchette, J., Vanounou, T., & Pelletier, J. S. (2018). Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. HPB (Oxford), 20(10), 905-915. doi:10.1016/j.hpb.2018.04.001

• 2016

  Radioiodine therapy versus antithyroid medications for Graves' disease.

  Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2016). Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev, 2, Cd010094. doi:10.1002/14651858.CD010094.pub2

• 2016

  Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.

  Li, H. X., Xiang, N., Hu, W. K., & Jiao, X. L. (2016). Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest, 39(11), 1225-1233. doi:10.1007/s40618-016-0484-y

• 2016

  Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.

  Rognoni, C., Ciani, O., Sommariva, S., Facciorusso, A., Tarricone, R., Bhoori, S., & Mazzaferro, V. (2016). Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 7(44), 72343-72355. doi:10.18632/oncotarget.11644

• 2015

  Recombinant human thyrotropin before (131)I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials.

  Lee, Y. Y., Tam, K. W., Lin, Y. M., Leu, W. J., Chang, J. C., Hsiao, C. L., . . . Hsieh, A. T. (2015). Recombinant human thyrotropin before (131)I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf), 83(5), 702-710. doi:10.1111/cen.12654

• 2015

  Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.

  Al-Adra, D. P., Gill, R. S., Axford, S. J., Shi, X., Kneteman, N., & Liau, S. S. (2015). Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol, 41(1), 120-127. doi:10.1016/j.ejso.2014.09.007

• 2014

  (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis.

  van Hulsteijn, L. T., Niemeijer, N. D., Dekkers, O. M., & Corssmit, E. P. (2014). (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf), 80(4), 487-501. doi:10.1111/cen.12341

• 2012

  SNMMI Procedure Standard for Therapy of Thyroid Disease with 131I (Sodium Iodide) 3.0 (2012)

  Silberstein, E. B., Alavi, A., Balon, H. R., Clarke, S. E., Divgi, C., Gelfand, M. J., . . . Waxman, A. D. (2012). The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med, 53(10), 1633-1651. doi:10.2967/jnumed.112.105148

• 2012

  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

  Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., . . . Benhamou, E. (2012). Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 366(18), 1663-1673. doi:10.1056/NEJMoa1108586

• 2012

  Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis.

  D'Angelo, G., Sciuto, R., Salvatori, M., Sperduti, I., Mantini, G., Maini, C. L., & Mariani, G. (2012). Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis. Q J Nucl Med Mol Imaging, 56(6), 538-543.

• 2011

  EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds (2011)

  Giammarile, F., Bodei, L., Chiesa, C., Flux, G., Forrer, F., Kraeber-Bodere, F., . . . Dosimetry, C. (2011). EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging, 38(7), 1393. Retrieved from https://doi.org/10.1007/s00259-011-1812-2. doi:10.1007/s00259-011-1812-2

• 2010

  EANM procedure guidelines for therapy of benign thyroid disease (2010)

  Stokkel, M. P. M., Handkiewicz Junak, D., Lassmann, M., Dietlein, M., & Luster, M. (2010). EANM procedure guidelines for therapy of benign thyroid disease. European Journal of Nuclear Medicine and Molecular Imaging, 37(11), 2218-2228. Retrieved from https://doi.org/10.1007/s00259-010-1536-8. doi:10.1007/s00259-010-1536-8

• 2008

  EANM procedure guideline for treatment of refractory metastatic bone pain (2008)

  Bodei, L., Lam, M., Chiesa, C., Flux, G., Brans, B., Chiti, A., & Giammarile, F. (2008). EANM procedure guideline for treatment of refractory metastatic bone pain. European Journal of Nuclear Medicine and Molecular Imaging, 35(10), 1934. Retrieved from https://doi.org/10.1007/s00259-008-0841-y. doi:10.1007/s00259-008-0841-y

• 2008

  EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy (2008)

  Giammarile, F., Chiti, A., Lassmann, M., Brans, B., & Flux, G. (2008). EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European Journal of Nuclear Medicine and Molecular Imaging, 35(5), 1039-1047. Retrieved from https://doi.org/10.1007/s00259-008-0715-3. doi:10.1007/s00259-008-0715-3

• 2008

  Guidelines for radioiodine therapy of differentiated thyroid cancer (2008)

  Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., . . . Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 35(10), 1941. Retrieved from https://doi.org/10.1007/s00259-008-0883-1. doi:10.1007/s00259-008-0883-1

• 2007

  EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases (2007)

  Tennvall, J., & Brans, B. (2007). EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 34(8), 1324-1327. Retrieved from https://doi.org/10.1007/s00259-007-0407-4. doi:10.1007/s00259-007-0407-4

• 2006

  EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin) (2006)

  Tennvall, J., Fischer, M., Bischof Delaloye, A., Bombardieri, E., Bodei, L., Giammarile, F., . . . Brans, B. (2007). EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging, 34(4), 616-622. doi:10.1007/s00259-007-0372-y

• 2003

  SNMMI Procedure Standard for Palliative Treatment for Painful Bone Metastases 3.0 (2003)

  Paszkowski, A. L., Hewitt, D. J., & Taylor, A., Jr. (1999). Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med, 24(11), 852-854. doi:10.1097/00003072-199911000-00006

• 2002

  EANM Procedure Guidelines for Radiosynovectomy (2002)

  Clunie, G., & Fischer, M. (2003). EANM procedure guidelines for radiosynovectomy. Eur J Nucl Med Mol Imaging, 30(3), Bp12-16. doi:10.1007/s00259-002-1058-0

• 2002

  Guidelines for 131I – ethiodised oil [Lipiodol] Therapy (2002)

  Guidelines for 131I-ethiodised oil (Lipiodol) therapy. (2003). Eur J Nucl Med Mol Imaging, 30(3), Bp20-22. doi:10.1007/s00259-002-1060-6

Therapy

• 2021

  The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study

  AHMADZADEHFAR, H., et al., The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [(177)Lu]Lu-PSMA-617: a WARMTH multicentre study, Eur J Nucl Med Mol Imaging 48 12 (2021) 4067-4076.

• 2021

  Pain Palliation of Bone Metastases: Production, Quality control and Dosimetry of Radiopharmaceuticals

  KUDO, T., et al., Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia: The IAEA INCAPS-COVID Study, JACC ASIA 1 2 (2021) 187-199.

• 2020

  Selective internal radiation therapy of hepatic tumors: Morphologic and functional imaging for voxel-based computer-aided dosimetry

  SKANJETI, A., et al., Selective internal radiation therapy of hepatic tumors: Morphologic and functional imaging for voxel-based computer-aided dosimetry, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 132 (2020) 110865.